Oncotarget

Research Papers:

Crosstalk among the proteome, lysine phosphorylation, and acetylation in romidepsin-treated colon cancer cells

Tian-Yun Wang _, Yu-Rong Chai, Yan-Long Jia, Jian-Hui Gao, Xiao-Jun Peng and Hua-Feng Han

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:53471-53501. https://doi.org/10.18632/oncotarget.10840

Metrics: PDF 1418 views  |   HTML 1690 views  |   ?  


Abstract

Tian-Yun Wang1,2, Yu-Rong Chai3, Yan-Long Jia4, Jian-Hui Gao2, Xiao-Jun Peng5, Hua-Feng Han5

1Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Henan, 453003, China

2Henan Collaborative Innovation Canter of Molecular Diagnosis and Laboratory Medicine, Xinxiang, Henan, 453003, China

3Department of Histology and Embryology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, 450001, China

4Pharmacy Collage, Xinxiang Medical University, Xinxiang, Henan, 453003, China

5Jingjie PTM BioLab (Hangzhou) Co. Ltd, Hangzhou, 310018, China

Correspondence to:

Tian-Yun Wang, email: wtianyuncn@126.com

Keywords: romidepsin, colon cancer, histone lysine-acetylation, proteome, histone lysine-phosphorylation

Received: November 13, 2015     Accepted: July 17, 2016     Published: July 26, 2016

ABSTRACT

Romidepsin (FK228) is one of the most promising histone-deacetylase inhibitors due to its potent antitumor activity, and has been used as a practical option for cancer therapy. However, FK228-induced changes in protein modifications and the crosstalk between different modifications has not been reported. To better understand the underlying mechanisms of FK228-related cancer therapy, we investigated the acetylome, phosphorylation, and crosstalk between modification datasets in colon cancer cells treated with FK228 by using stable-isotope labeling with amino acids in cell culture and affinity enrichment, followed by high-resolution liquid chromatography tandem mass spectrometry analysis. In total, 2728 protein groups, 1175 lysine-acetylation sites, and 4119 lysine-phosphorylation sites were quantified. When the quantification ratio thresholds were set to > 2.0 and < 0.5, respectively, a total of 115 and 38 lysine-acetylation sites in 85 and 32 proteins were quantified as increased and decreased targets, respectively, and 889 and 370 lysine-phosphorylation sites in 599 and 289 proteins were quantified as increased and decreased targets, respectively. Furthermore, we identified 274 proteins exhibiting both acetylation and phosphorylation modifications. These findings indicated possible involvement of these proteins in FK228-related treatment of colon cancer, and provided insight for further analysis of their biological function.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10840